Skip to contentI
Inhibitor Therapeutics, Inc.
I
INTIInhibitor Therapeutics, Inc. Q1 2020 · 10-Q
Revenue$0.00$0.00— vs Q1 2019 Net Income-$384.42K-$384.42KN/M vs Q1 2019 EPS Diluted$0.00$0.00— vs Q1 2019 Operating Income-$385,442N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Inhibitor Therapeutics, Inc. · CIK 1042418 · Engraved from SEC EDGAR
ended Mar 31, 2020 · filed May 1, 2020 · 31 d after period end